Development and in vivo evaluation of functionalized ritonavir proliposomes for lymphatic targeting

Ahammed, Vasif; Narayan, Reema; Paul, John; Nayak, Yogendra; Roy, Bisakha; Shavi, Gopal Venkatesh; Nayak, Usha Yogendra

doi:10.1016/j.lfs.2017.06.022

Cited by 30 publications

(18 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[76][77][78] Finally, in thymus tissue only ritonavir data have been generated to date, which demonstrate slightly lower (1.3-fold) concentrations compared with blood plasma in rats. 80 Interestingly, ritonavir is a known P-gp substrate which increases in activity as thymocytes mature. 81 Thus, age may be an important determinant of distribution into the thymus for P-gp substrates like the PIs.…”

Section: Other Deep Tissuesmentioning

confidence: 99%

“…In kidney tissue, rats exhibit TPRs of 5, 116, and 930 for maraviroc, tenofovir, and darunavir, respectively 76–78 . Finally, in thymus tissue only ritonavir data have been generated to date, which demonstrate slightly lower (1.3‐fold) concentrations compared with blood plasma in rats 80 . Interestingly, ritonavir is a known P‐gp substrate which increases in activity as thymocytes mature 81 .…”

Section: Pharmacology In the Hiv Reservoirmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacology of HIV Cure: Site of Action

Devanathan

Cottrell

2021

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Despite significant advances in HIV treatment over the past 30 years, critical barriers to an HIV cure persist. The HIV reservoir, defined at both the cellular and anatomical level, constitutes the main barrier to cure. While the mechanisms underlying the reservoir are not yet well understood, one theory to explain persistence at the anatomical level is that subtherapeutic exposure to antiretroviral therapy (ART) within certain tissue compartments permits ongoing replication. Characterizing ART pharmacology throughout the body is important in the context of these potential pharmacologic sanctuaries and for maximizing the probability of success with forthcoming cure strategies that rely on latency reversal and require ART to prevent reseeding the reservoir. In this review, we provide a comprehensive overview of ART and latency reversal agent distribution at the site of action for HIV cure (i.e., anatomical sites commonly associated with HIV persistence, such as lymphoid organs and the central nervous system). We also discuss methodologic approaches that provide insight into HIV cure pharmacology, including experimental design and advances within the computational, pharmaceutical, and analytical chemistry fields. The information discussed in this review will assist in streamlining the development of investigational cure strategies by providing a roadmap to ensure therapeutic exposure within the site of action for HIV cure.

show abstract

Section: Other Deep Tissuesmentioning

confidence: 99%

Section: Pharmacology In the Hiv Reservoirmentioning

confidence: 99%

Pharmacology of HIV Cure: Site of Action

Devanathan

Cottrell

2021

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

show abstract

“…Typically, only drugs with logP values between 1 and 3 have favorable oral absorption profiles [149]. Most ARV drugs are outside this range (Tables 3 to 5), being either extremely hydrophilic (e.g., ddI [150] and AZT [130]) or highly lipophilic (e.g., LPV [66,71,83,112], RTV [114], EFV [16,75,140], SQV [90,136], EFZ [142] and ATV [86]). Therefore, lipid-based nanocarriers may help ARV drugs achieving a balanced lipophilic/hydrophilic nature.…”

Section: Tuning the Physicochemical Properties Of Lipid-based Nanocarriers To Overcome Biological Barriersmentioning

confidence: 99%

“…For example, following oral administration, biotinylated liposomes of insulin were observed to permeate the GI tract via a facilitated absorption mechanism [151]. Based on this study, liposomes were coated with biotin (biotinylated proliposomes) in order to improve uptake of RTV into the intestinal lymphatic tissues [114]. Another example is the SLN grafting with a peptide that is specific for CD4+ receptors present on T cells, which improved specific DRV uptake by HIV host cells [82].…”

Section: Tuning the Physicochemical Properties Of Lipid-based Nanocarriers To Overcome Biological Barriersmentioning

confidence: 99%

Lipid Nanocarriers for Anti-HIV Therapeutics: a Focus on Physicochemical Properties and Biotechnological Advances

Faria¹,

Lopes²,

Neves³

et al. 2021

Preprint

View full text Add to dashboard Cite

Since HIV was first identified, and in a relatively short period of time, AIDS has become one of the most devastating infectious diseases of the 21st century. Classical antiretroviral therapies were a major step forward in disease treatment options, significantly improving the survival rates of HIV-infected individuals. Even though these therapies have greatly improved HIV clinical outcomes, antiretrovirals (ARV) feature biopharmaceutic and pharmacokinetic problems such as poor aqueous solubility, short half-life and poor penetration into HIV reservoir sites, which contribute to the sub-optimal efficacy of these regimens. To overcome some of these issues, novel nanotechnology-based strategies for ARV delivery towards HIV viral reservoirs have been proposed. The current review focus on the benefits of using lipid-based nanocarriers for tuning the physicochemical properties of ARVs to overcome biological barriers upon administration. Furthermore, a correlation of these properties and the potential therapeutic outcomes has been established. Biotechnological advancements using lipid nanocarriers for RNA interference delivery for the treatment of HIV infections were also discussed.

show abstract

“…Due to its advantages over the liposomal formulations, the researches have stated that one-step spray drying method can be implemented in the production of proliposomes of rifapentine-loaded proliposomes for the treatment of tuberculosis; the study conducted revealed 7 fold increase in both, the mean residence time and t 1/2 (Patil-Gadhe and Pokharkar, 2014b). Proliposomal ritonavir formulation for lymphatic targeting has been also developed and reported for its accelerated long term stability tests, in-vitro drug release and in-vivo pharmacokinetics (Ahammed, 2017). PL can be prepared by methods such as ilm deposition, spray-drying, modi ied ethanol injection method, lyophilisation, supercritical anti-solvent technology, etc.…”

Section: Proliposomesmentioning

confidence: 99%

Recent updates on dry powder for inhalation for pulmonary drug delivery systems

Deshkar

Vas

2019

ijrps

View full text Add to dashboard Cite

Pulmonary drug delivery system is an attractive and most promising approach which is gaining great impetus for the delivery of various therapeutic agents which includes administration of proteins and peptides, agents for the treatment of tuberculosis, asthma, diabetes chronic obstructive pulmonary diseases (COPD), various fungal infections, cancer, etc. This route has gained great importance due to its large surface and the absorptive area, which can potentially bypass the hepatic first-pass metabolism. The dawn of nanotechnology has brought a lot of advancement in the pre-existing formulation aspect with respect to reducing the systemic toxicity and dosing, specific targeting and enhanced efficiency of the treatment. This review reflects on the basics of pulmonary drug delivery, various formulations options available for administration via dry powder inhalers and advances in the same.

show abstract

Development and in vivo evaluation of functionalized ritonavir proliposomes for lymphatic targeting

Cited by 30 publications

References 28 publications

Pharmacology of HIV Cure: Site of Action

Pharmacology of HIV Cure: Site of Action

Lipid Nanocarriers for Anti-HIV Therapeutics: a Focus on Physicochemical Properties and Biotechnological Advances

Recent updates on dry powder for inhalation for pulmonary drug delivery systems

Contact Info

Product

Resources

About